Tag: Granulomatosis with polyangiitis

1. In this randomized controlled trial involving patients with antineutrophil cytoplasmic antibody-associated vasculitis in complete remission, administration of rituximab for an additional 18 months was associated with a lower likelihood of relapse versus placebo. 2. Although the vast majority of patients in both groups reported at least 1 adverse event,...
1. In this study of decedents from 1999 to 2017, mortality due to antineutrophil cytoplasmic autoantibody-associated vasculitis (AAV) -related illness was found to have decreased by an average of 1.6% per year. 2. Following stratification, non-Hispanic whites, men, and Midwesterners appeared to be disproportionately affected by AAV, but it remained...
Image: PD/Rituximab (Rituxan, MabThera) 1. At 18 months, patients with ANCA-associated vasculitis treated with one course of rituximab had similar outcomes in terms of inducing remission when compared to patients treated with conventional continuous immunosuppression therapy. 2. The overall rate of adverse events was similar between both groups; however, patients treated with rituximab had lower...